New drug duo aims to shrink deadly eye cancer

NCT ID NCT06121180

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 24 times

Summary

This study tests whether two drugs, cemiplimab and ziv-aflibercept, can shrink or stop the growth of metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. About 32 adults with this condition will receive the combination treatment. The main goal is to see how many patients' tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Northwell Health Center for Advanced Medicine

    RECRUITING

    New Hyde Park, New York, 11042, United States

    Contact

  • The Angeles Clinic and Research Institute

    RECRUITING

    Los Angeles, California, 90025, United States

    Contact

  • University of Chicago Medical Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact

Conditions

Explore the condition pages connected to this study.